Chymase inhibitor improves survival in hamsters with myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 41, Issue SUPPL. 1, 2003, Pages

  Hoshino, Fumihiro ^a   Urata, Hidenori ^a   Inoue, Yukiko ^a   Saito, Yuri ^a   Yahiro, Eiji ^a   Ideishi, Munehito ^a   Arakawa, Kikuo ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Angiotensin II forming enzyme; Angiotensin converting enzyme; Cardiac remodeling; Congestive heart failure; Renin angiotensin system

Indexed keywords

4 [1 (NAPHTHYLMETHYL)BENZIMIDAZOL 2 YLTHIO]BUTANOIC ACID; ANGIOTENSIN; ANGIOTENSIN I; BUTYRIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN; TEI E 548; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG INHIBITION; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; LONG TERM CARE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SURVIVAL RATE; SYRIAN HAMSTER;

ANIMALS; CHYMASES; CRICETINAE; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; HUMANS; MESOCRICETUS; MYOCARDIAL INFARCTION; SERINE ENDOPEPTIDASES; SURVIVAL RATE;

EID: 0037214324     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72.
2. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992;54:227-41.
3. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23.
4. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-82.
5. Ihara M, Urata H, Shirai K, et al. High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 2000;94:247-53.
6. Meggs LG, Coupet J, Huang H, et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993;72:1149-62.
7. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25:1369-80.
8. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens Suppl 1994;12:S17-22.
9. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998;32:514-20.
10. Wang Z, Walter M, Selwood T, Rubin H, Schechter NM. Recombinant expression of human mast cell proteases chymase and tryptase. Biol Chem 1998;379:167-74.
11. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
12. He S, Walls AF. The induction of a prolonged increase in microvascular permeability by human mast cell chymase. Eur J Pharmacol 1998;352:91-8.
13. Stauss HM, Zhu YC, Redlich T, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: Bradykinin versus angiotensin II. J Cardiovasc Risk 1994;1:255-62.
14. Urata H, Tanabe Y, Kiyonaga A, et al. Antihypertensive and volume-depleting effects of mild exercise on essential hypertension. Hypertension 1987;9:245-52.
15. Urata H, Khosla MC, Bumpus FM, Husain A. Evidence for extracellular, but not intracellular, generation of angiotensin II in the rat adrenal zona glomerulosa. Proc Natl Acad Sci USA 1988;85:8251-5.
16. Kovacs SJ, Rosado J, Manson McGuire AL, Hall AF. Can trasmitral Doppler E-waves differentiate hypertensive hearts from normal? Hypertension 1997;30:788-95.
17. Anderson KP. Sudden death, hypertension, and hypertrophy. J Cardiovasc Pharmacol 1984;6:S498-503.
18. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
19. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995;25:879-84.
20. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 2001;86:203-14.
21. Falkenhahn M, Franke F, Bohle RM, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995;25:219-26.
22. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995;95:46-54.
23. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
24. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
25. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: Beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
26. Wollert KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-67.
27. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: Captopril versus losartan. J Am Coll Cardiol 1996;27:714-9.
28. Takai S, Jin D, Nishimoto M, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 2001;69:1725-32.
29. Takai S, Jin D, Sakaguchi M, Kirimura K, Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol 2001;86:124-6.